EMILY ALEXIADIS: Open Payments
NPI 1891297073 · TARZANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,533 in 14 payments from 11 companies in 2025. Trend: 2023 $788 · 2024 $1,530 · 2025 $1,533
Food & beverage: $1,533
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 3 | $400 |
| Genentech, Inc. | 1 | $142 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| ABBVIE INC. | 1 | $125 |
| Abbott Laboratories | 1 | $122 |
| ARGENX US, INC. | 1 | $122 |
| Biogen, Inc. | 1 | $118 |
| AstraZeneca Pharmaceuticals LP | 1 | $116 |
| Neurocrine BioSciences, Inc. | 1 | $114 |
| Axsome Therapeutics, Inc. | 1 | $101 |
Products named: REPATHA, VOQUEZNA, DALVANCE, TAVNEOS, ALINITY, VYVGART, ZURZUVAE, LOKELMA.
Industry payments across CA — which companies pay providers there.
